Antimicrobial and anti-inflammatory peptides

Abstract

Antimicrobial and/or anti-inflammatory peptide compositions and therapeutic uses thereof are provided. The peptides and analogs or derivatives thereof may be used as an antimicrobial agent and/or as an anti-inflammatory agent. In certain embodiments, the peptides are cationic peptides. The peptides are useful for the treatment of inflammatory diseases, such as microorganism-caused infections, acne , and psoriasis. The peptides and peptide formulations may be used topically or parenterally.

1 .- 24 . (canceled) 
     
     
         25 . A method for treating or ameliorating inflammation in a subject with atopic dermatitis, comprising administering to the subject an anti-inflammatory peptide of up to 35 amino acids comprising 11B7 (SEQ ID NO: 23). 
     
     
         26 . The method according to  claim 25 , wherein the anti-inflammatory peptide is at a concentration of about 0.01% to about 10%. 
     
     
         27 . The method according to  claim 26 , wherein the anti-inflammatory peptide is at a concentration of about 0.5% to about 5%. 
     
     
         28 . The method according to  claim 27 , wherein the anti-inflammatory peptide is at a concentration of about 1% to about 3%. 
     
     
         29 . The method according to  claim 25 , wherein the inflammation is selected from the group consisting of acute, adhesive, atrophic, catarrhal, chronic, croupous, degenerative, exudative, fibrinopurulent, fibrinous, granulomatous, interstitial, intraepithelial, necrotic, proliferative, pseudomembranous, purulent, sclerosing, serofibrinous, serous, and subacute. 
     
     
         30 . The method according to  claim 25 , wherein the anti-inflammatory peptide is administered in combination with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         31 . The method according to  claim 25 , wherein the anti-inflammatory peptide is administered concurrently with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         32 . The method according to  claim 25 , wherein the anti-inflammatory peptide is administered sequentially with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         33 . The method according to  claim 25 , wherein the peptide has one or more amino acids altered to a corresponding D-amino acid. 
     
     
         34 . The method according to  claim 25 , wherein the peptide is amidated at the C-terminal amino acid. 
     
     
         35 . The method according to  claim 25 , wherein the peptide is acetylated at the N-terminal amino acid. 
     
     
         36 . The method according to  claim 25 , wherein the administration is topical. 
     
     
         37 . A method for preventing the recurrence of inflammation in a subject with atopic dermatitis, comprising administering to the subject an anti-inflammatory peptide of up to 35 amino acids comprising 11B7 (SEQ ID NO: 23). 
     
     
         38 . The method according to  claim 37 , wherein the anti-inflammatory peptide is at a concentration of about 0.01% to about 10%. 
     
     
         39 . The method according to  claim 38 , wherein the anti-inflammatory peptide is at a concentration of about 0.5% to about 5%. 
     
     
         40 . The method according to  claim 39 , wherein the anti-inflammatory peptide is at a concentration of about 1% to about 3%. 
     
     
         41 . The method according to  claim 37 , wherein the inflammation is selected from the group consisting of acute, adhesive, atrophic, catarrhal, chronic, croupous, degenerative, exudative, fibrinopurulent, fibrinous, granulomatous, interstitial, intraepithelial, necrotic, proliferative, pseudomembranous, purulent, sclerosing, serofibrinous, serous, and subacute. 
     
     
         42 . The method according to  claim 37 , wherein the anti-inflammatory peptide is administered in combination with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         43 . The method according to  claim 37 , wherein the anti-inflammatory peptide is administered concurrently with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         44 . The method according to  claim 37 , wherein the anti-inflammatory peptide is administered sequentially with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         45 . The method according to  claim 37 , wherein the peptide has one or more amino acids altered to a corresponding D-amino acid. 
     
     
         46 . The method according to  claim 37 , wherein the peptide is amidated at the C-terminal amino acid. 
     
     
         47 . The method according to  claim 37 , wherein the peptide is acetylated at the N-terminal amino acid. 
     
     
         48 . The method according to  claim 37 , wherein the administration is topical. 
     
     
         49 . A method for preventing inflammation in a subject with atopic dermatitis, comprising administering to the subject an anti-inflammatory peptide of up to 35 amino acids comprising 11B7 (SEQ ID NO: 23). 
     
     
         50 . The method according to  claim 49 , wherein the anti-inflammatory peptide is at a concentration of about 0.01% to about 10%. 
     
     
         51 . The method according to  claim 50 , wherein the anti-inflammatory peptide is at a concentration of about 0.5% to about 5%. 
     
     
         52 . The method according to  claim 51 , wherein the anti-inflammatory peptide is at a concentration of about 1% to about 3%. 
     
     
         53 . The method according to  claim 49 , wherein the inflammation is selected from the group consisting of acute, adhesive, atrophic, catarrhal, chronic, croupous, degenerative, exudative, fibrinopurulent, fibrinous, granulomatous, interstitial, intraepithelial, necrotic, proliferative, pseudomembranous, purulent, sclerosing, serofibrinous, serous, and subacute. 
     
     
         54 . The method according to  claim 49 , wherein the anti-inflammatory peptide is administered in combination with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         55 . The method according to  claim 49 , wherein the anti-inflammatory peptide is administered concurrently with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         56 . The method according to  claim 49 , wherein the anti-inflammatory peptide is administered sequentially with an anti-inflammatory agent, an antimicrobial agent, an anti-fungal agent, or an anti-viral agent. 
     
     
         57 . The method according to  claim 49 , wherein the peptide has one or more amino acids altered to a corresponding D-amino acid. 
     
     
         58 . The method according to  claim 49 , wherein the peptide is amidated at the C-terminal amino acid. 
     
     
         59 . The method according to  claim 49 , wherein the peptide is acetylated at the N-terminal amino acid. 
     
     
         60 . The method according to  claim 49 , wherein the administration is topical. 
     
     
         61 . The method according to  claim 25 , wherein the inflammation is not caused by a microbial infection. 
     
     
         62 . The method according to  claim 37 , wherein the inflammation is not caused by a microbial infection. 
     
     
         63 . The method according to  claim 49 , wherein the inflammation is not caused by a microbial infection.